BPC-157 vs TB-500: Differences, Stacking and Which to Choose

BPC-157 and TB-500 are two of the most discussed peptides in the tissue-repair research literature, and they are often mentioned in the same sentence. They are different molecules with different reference profiles, and the question people ask most is whether to study them separately or together. This is a neutral, third-person comparison of how they differ, when protocols describe stacking them, and the reconstitution math for each.

Both are research compounds, not approved for human consumption, and nothing here is medical or dosing advice. The numbers below are arithmetic conversions you can verify with the BPC-157 calculator and the matching TB-500 tool. Any decision about use belongs with a licensed clinician.

What each peptide is

BPC-157 (Body Protection Compound 157) is a short synthetic peptide derived from a sequence found in gastric juice. TB-500 is a synthetic fragment of thymosin beta-4, a protein present in many tissues. They are studied for overlapping repair pathways but are not the same compound and are not interchangeable.

• BPC-157: typically a 5 mg or 10 mg lyophilized vial. Research figures are commonly discussed in a 250 to 500 mcg range.
• TB-500: typically a 2 mg, 5 mg, or 10 mg vial. Research figures are commonly discussed in a 2 mg to 5 mg per-week range, often split across the week.
• Both ship as freeze-dried powder and must be reconstituted with bacteriostatic water before any volume can be drawn.

Localized vs systemic: the core difference

The most cited distinction in the literature is reach. BPC-157 is frequently described as having a more localized profile, which is why some research protocols place an injection near an area of interest. TB-500 is more often described as systemic, distributing more broadly through the body regardless of injection site.

• BPC-157: often framed as localized or site-directed in research settings.
• TB-500: often framed as systemic, spreading more widely after injection.
• Frequency: BPC-157 references tend toward daily figures; TB-500 references tend toward a larger weekly amount split into one or two administrations.

Why protocols pair them

The rationale described for stacking the two is that their profiles are complementary rather than redundant. A localized compound and a systemic compound cover different reference pathways, so some research protocols run them together rather than choosing one. This is a description of how stacks are structured in the literature, not a recommendation to combine them.

If you are reading about a stack, two mechanical points matter. First, each peptide has its own vial strength and its own concentration, so the unit counts are almost never the same. Second, whether two peptides can share a single syringe is a handling question covered separately in can you mix two peptides in one syringe. Run each one through its own math before assuming anything about a combined draw.

Dosing math, side by side

The arithmetic is identical for both: concentration sets everything. Concentration = vial strength / water volume. Draw volume = dose / concentration. Units = draw volume x 100 on a U-100 insulin syringe. Here is a worked example for each at a clean reference setup.

• BPC-157, 10 mg vial in 2 mL = 5 mg/mL (5000 mcg/mL). A 250 mcg figure = 0.05 mL = 5 units.
• BPC-157, 5 mg vial in 2 mL = 2.5 mg/mL. The same 250 mcg = 0.10 mL = 10 units.
• TB-500, 5 mg vial in 2 mL = 2.5 mg/mL (2500 mcg/mL). A 2 mg (2000 mcg) figure = 0.80 mL = 80 units.
• TB-500, 5 mg vial in 2.5 mL = 2 mg/mL. The same 2 mg = 1.0 mL = 100 units, the full barrel of a 1 mL syringe.

Two things stand out. TB-500 figures are stated in milligrams and BPC-157 figures in micrograms, so it is easy to misread a decimal point if you switch between them. And the TB-500 draw volumes are far larger, which is why diluent choice changes whether a figure fits on one syringe. Recompute from scratch whenever the vial size, water volume, or target changes. For the full procedure, see how to reconstitute peptides and the per-step reconstitution calculator.

Which to read up on first

There is no single answer, because these are research compounds and the choice is not a medical one to make from an article. As a framework for understanding the literature: protocols centered on a single area of interest more often reference BPC-157 alone, protocols described as broad or systemic more often reference TB-500, and protocols that want both profiles reference the pair. Compare the depth in BPC-157 dosage guide and TB-500 dosage guide, and explore the full peptides directory for adjacent compounds.

Whatever you read, the math is the part you can get exactly right. Set the concentration first, log every vial and water volume so the numbers stay reproducible, and see the disclaimer for the limits of this reference information.